Peptides News and Research

RSS

Palatin introduces clinical trial website in support of bremelanotide phase 3 study for FSD treatment

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has launched a clinical trial website in support of its phase 3 reconnect study with bremelanotide for the treatment of female sexual dysfunction (FSD).

20 Feb 2015

Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Cancer vaccines are designed to turn the body's own immune system specifically against tumor cells. Particularly promising are vaccines that are directed against so-called neoantigens: These are proteins that have undergone a genetic mutation in tumor cells and, therefore, differ from their counterparts in healthy cells.

20 Feb 2015

Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Nanometer-sized "drones" that deliver a special type of healing molecule to fat deposits in arteries could become a new way to prevent heart attacks caused by atherosclerosis, according to a study in pre-clinical models by scientists at Brigham and Women's Hospital and Columbia University Medical Center.

19 Feb 2015

Doctoral students of Magicbullet network to develop 'gentle' cancer treatment

Medication that specifically targets cancer cells and delivers its active agent without harming healthy cells - this is what doctoral students of the Magicbullet network will be working on from mid-2015. Bielefeld University is coordinating the programme for the development of "gentle" cancer treatment.

19 Feb 2015

University of Alberta researcher named winner of A.S.P.E.N.'s 2015 Harry M. Vars Award

David Lim, MD, CM, of the University of Alberta has been named the winner of the 2015 Harry M. Vars Award by the American Society for Parenteral and Enteral Nutrition. The award is for his research on parenteral nutrition associated liver disease (PNALD) in infants, which was presented at A.S.P.E.N.'s Clinical Nutrition Week conference in Long Beach, California, February 14 to 17.

19 Feb 2015

Rutgers researchers study rare form of gum disease that affects African-American adolescents

Oral biologist Daniel H. Fine and his team at Rutgers School of Dental Medicine have tracked more than 2,500 Newark children since 2007 to chart the progression of a rare form of gum disease that afflicts African-American adolescents.

19 Feb 2015

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S.

18 Feb 2015

UT Arlington chemist receives NIH's Academic Research Enhancement Award for protein research

A University of Texas at Arlington bio-analytical chemist exploring proteins, their structures and functions by using cutting-edge analytical instrumentation called mass spectrometry has received an Academic Research Enhancement Award from the National Institutes of Health.

18 Feb 2015

CAMH scientists discover potential new approach to treat multiple sclerosis

Scientists at the Centre for Addiction and Mental Health have discovered a promising new approach to treat multiple sclerosis (MS). In a new study, they've identified a previously unknown change in the spinal cord related to MS, and a way to alter this change to reduce the nerve cell damage that occurs with the disease.

18 Feb 2015

Synthetic DNA gel could bring researchers closer to printing artificial organs

A two-part water-based gel made of synthetic DNA and peptide could bring the inventors of a 3D bio printer closer to being able to print organs for transplant, or to replace animal testing. The teams led by Dongsheng Liu (Tsinghua University) and Will Shu (Heriot-Watt University) faced two main challenges: finding a matrix or scaffold to support the live cells in 3D, and being able to produce a consistent product which would not be rejected by transplant recipients.

11 Feb 2015

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma Inc., a U.S. privately-held biopharma company, announced today that results from a multicenter Phase III study of the investigational new drug, octreotide capsules, were published online for early release on Feb. 9, ahead of print, by the Journal of Clinical Endocrinology & Metabolism.

10 Feb 2015

IU researchers awarded NIH grant to develop new weapon to fight against antibiotic-resistant bacteria

The alarming increase of antibiotic-resistant bacteria poses health and economic threats worldwide, with more than 2 million Americans infected by the bacteria each year. Now, a team of Indiana University chemists and biologists has been awarded a major grant to develop and use a chemical tagging method to better understand how bacteria build their cell wall, which is still the best target for new antibiotics.

10 Feb 2015

New findings could pave way to develop drug therapies for necrosis-related diseases

Strokes, heart attacks and traumatic brain injuries are separate diseases with certain shared pathologies that achieve a common end - cell death and human injury due to hypoxia, or lack of oxygen.

9 Feb 2015

Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

Helsinn Healthcare S.A. and Zealand Pharma A/S jointly announce that Helsinn has started a Phase IIB clinical dose-finding trial of elsiglutide for the prevention of chemotherapy-induced diarrhea (CID). The first patients out of a planned total of 600 patients with colorectal cancer treated with chemotherapy have been dosed in the trial.

8 Feb 2015

University of Alberta's David Lim named recipient of Research Trainee Award by A.S.P.E.N.

David Lim, MD, CM, of the University of Alberta has been named a Research Trainee Award recipient by the American Society for Parenteral and Enteral Nutrition. The award is for his research on parenteral nutrition associated liver disease (PNALD) in infants that he will present at A.S.P.E.N.'s Clinical Nutrition Week conference in Long Beach, California, February 14 to 17.

6 Feb 2015

Newly found peptide may reduce desire for food

Researchers have identified a peptide and hormone that when administered to a specific area of the brain may reduce the desire for food. The study, which appears in the journal Neuropsychopharmacology, may one day lead to medications that treat obesity and binge eating disorders.

5 Feb 2015

Biodegradable microstructures may help repair tissue, prevent heart failure

The delivery of tiny biodegradable microstructures to heart tissue damaged by heart attack may help repair the tissue and prevent future heart failure. A team led by cardiovascular researchers at the Medical College of Wisconsin bioengineered the microstructures to be the same size, shape and stiffness as adult heart muscle cells, or cardiomyocytes, with the goal of releasing biologically active peptides that act as cardioprotective agents.

5 Feb 2015

ISP shows promise in stopping fatal arrhythmias after heart attack

Case Western Reserve's chemical compound aimed at restoring spinal cord function may have an additional purpose: stopping potentially fatal arrhythmias after heart attack.

3 Feb 2015

Using NMR to study influenza and TB: an interview with Dr. Tim Cross

In this interview, Tim Cross, Director of the NMR and MRI programs at the National High Magnetic Field Lab (NHMFL) in Tallahassee, Florida, talks about his research into protein structures in viruses and bacteria, and how the findings will affect medical research into disease prevention.

From Bruker BioSpin Division 3 Feb 2015

VG Life Sciences issues patent relating to treatment of IBD through CLIP-inducing agent

VG Life Sciences, (VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8906846, covering a method of treating inflammatory bowel disease (IBD) through the administration of a CLIP-inducing agent.

31 Jan 2015

Peptides News and Research

Palatin introduces clinical trial website in support of bremelanotide phase 3 study for FSD treatment

Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Targeted nanomedicines could help prevent heart attacks caused by atherosclerosis

Doctoral students of Magicbullet network to develop 'gentle' cancer treatment

University of Alberta researcher named winner of A.S.P.E.N.'s 2015 Harry M. Vars Award

Rutgers researchers study rare form of gum disease that affects African-American adolescents

Actavis provides overview of standalone global pharmaceutical development pipeline

UT Arlington chemist receives NIH's Academic Research Enhancement Award for protein research

CAMH scientists discover potential new approach to treat multiple sclerosis

Synthetic DNA gel could bring researchers closer to printing artificial organs

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

IU researchers awarded NIH grant to develop new weapon to fight against antibiotic-resistant bacteria

New findings could pave way to develop drug therapies for necrosis-related diseases

Helsinn begins elsiglutide Phase IIB trial for prevention of chemotherapy-induced diarrhea

University of Alberta's David Lim named recipient of Research Trainee Award by A.S.P.E.N.

Newly found peptide may reduce desire for food

Biodegradable microstructures may help repair tissue, prevent heart failure

ISP shows promise in stopping fatal arrhythmias after heart attack

Using NMR to study influenza and TB: an interview with Dr. Tim Cross

VG Life Sciences issues patent relating to treatment of IBD through CLIP-inducing agent

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News